Drug Trial Radar · NCT05221021
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Oct 1, 2022
Primary completion
Dec 30, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Walter Reed National Military Medical CenterFederal agency
- Sponsor type
- Federal agency
- First posted
- Feb 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.
Conditions
- Overactive Bladder Syndrome
Interventions
Vaginal estrogenDrug
0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
Mirabegron 50 MG [Myrbetriq]Drug
50mg oral Mirabegron once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- OAB-q short form (SF) symptom bother scoresTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Walter Reed National Military Medical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.